Investors & Media

press releases

Date Title Teaser
11/16/17
Summary ToggleCelgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma Designations based on preliminary clinical data from ongoing phase I study of bb2121 in heavily pre-treated multiple myeloma SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 16, 2017-- Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a
11/16/17
Summary Togglebluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype – Study to enroll approximately fifteen adult, adolescent and pediatric patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 16, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T
11/01/17
Summary Togglebluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting - 11 total abstracts accepted, including updated data from Northstar-2 (HGB-207) Phase 3 study of LentiGlobin in patients with TDT and non-β0/β0 genotypes, HGB-205 study of LentiGlobin in patients with SCD and TDT, and CRB-401 study of bb2121 anti-BCMA CAR T in patients with relapsed/refractory
11/01/17
Summary Togglebluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress - 11 presentations across severe genetic diseases, immunotherapy and gene editing programs to be presented at the American Society of Hematology (ASH) Annual Meeting – - Early data from patients treated under the amended study protocol in HGB-206 Phase 1 study in patients with severe sickle cell
10/31/17
Summary Togglebluebird bio Announces ASH Abstract Conference Call on November 1st and Upcoming Investor Events in November CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 31, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
10/06/17
Summary Togglebluebird bio to Present at Chardan Gene Therapy Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
10/04/17
Summary Togglebluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine – Additional follow-up data to be included in poster presentation at Child Neurology Society (CNS) Annual Meeting – – 15/17 (88%) of the patients infused with Lenti-D drug product remain alive and free of major functional disabilities (MFDs), the primary efficacy endpoint of the trial – – No
09/28/17
Summary Togglebluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma - Celgene has exercised its option to exclusively license bb21217 under its collaboration with bluebird bio – - bluebird bio to receive $15 million option exercise payment from Celgene - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 28, 2017-- bluebird bio, Inc.
09/20/17
Summary Togglebluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has appointed Mary
09/13/17
Summary Togglebluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401, Phase 1 Study of Anti-BCMA CAR T Therapy bb2121 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2017-- bluebird bio, Inc . (NASDAQ: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that the expansion cohort of
09/06/17
Summary Togglebluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD) at Child Neurology Society (CNS) 2017 Annual Meeting — Natural history and observational study data to be included in oral presentation at International Congress of Inborn Errors of Metabolism (ICIEM) — CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially
09/01/17
Summary Togglebluebird bio to Present at Investor Conferences in September CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
08/09/17
Summary Togglebluebird bio to Present at Wedbush PacGrow Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 9, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
08/02/17
Summary Togglebluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress – Completed enrollment in Northstar -2, Phase 3 study of LentiGlobin TM drug product in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes – – Presented updated clinical results from studies in relapsed/refractory multiple myeloma, TDT and severe sickle cell disease
06/27/17
Summary Togglebluebird bio Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 27, 2017-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of
06/26/17
Summary Togglebluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD) – 15/17 patients (88%) in initial study cohort remain free of major functional disabilities (MFDs) at 24 months – – Expansion cohort enrolling additional patients to gain European manufacturing experience – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 26, 2017-- bluebird bio, Inc.
06/23/17
Summary Togglebluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting –Ongoing transfusion independence up to 3.5 years in patients with transfusion-dependent β-thalassemia (TDT); three patients have discontinued iron chelation – –First patient with severe sickle cell disease (SCD) treated with gene therapy continues to show clinically meaningful improvement in
06/23/17
Summary Togglebluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting - Drug product vector copy number (DP VCN) and percentage of lentiviral vector positive cells (LVV+) for initial 7 drug product lots manufactured in Northstar -2 (HGB-207) are consistently higher than in Northstar (HGB-204) with median DP VCN of 3.0 – - Initial results show that the three patients
06/08/17
Summary Togglebluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has appointed John O.
06/05/17
Summary Togglebluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting – 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 10 6 ) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89% – – 73% of evaluable patients in active dose cohorts achieved a very good partial response (VGPR) or better; 27% complete
06/01/17
Summary Togglebluebird bio to Present at Two Investor Conferences in June CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
05/23/17
Summary Togglebluebird bio Announces Collaboration with Duke University’s Robert J. Margolis, MD, Center for Health Policy on Value-Based Payment Framework for Gene Therapy – Collaboration includes industry leaders; aims to develop strategies for sustainable, value-based approach to access transformative gene therapy treatments – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing
05/18/17
Summary Togglebluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting – Presentations include early data from Northstar -2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes and updated data from HGB-205 study in TDT and severe sickle cell disease (SCD) – – Encore presentation of data from CRB-401
05/17/17
Summary Togglebluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting –Presentation will include safety and efficacy data from 18 patients with up to 12 months of follow-up– –Company to host event with live webcast, Monday, June 5 , 6:30 p.m. CT– CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 17, 2017-- bluebird bio, Inc.
05/03/17
Summary Togglebluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress – Case study on first patient with severe sickle cell disease (SCD) treated with gene therapy published in New England Journal of Medicine – – Appointed Derek Adams, Ph.D. Chief Technology and Manufacturing Officer and Joanne Smith-Farrell , Ph.D.
05/02/17
Summary Togglebluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2017-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with GlaxoSmithKline Intellectual Property Development Limited (GSK).
05/02/17
Summary Togglebluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2017-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma AG . “bluebird bio is a pioneer in the field of lentiviral vector-based
04/26/17
Summary Togglebluebird bio to Present at Upcoming Investor Conferences CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 26, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
03/20/17
Summary Togglebluebird bio Appoints New Senior Manufacturing and Corporate Development Executives CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 20, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that Derek Adams , Ph.D.
03/01/17
Summary Togglebluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine – Patient treated with LentiGlobin TM drug product demonstrates high levels (~50% of total hemoglobin) of anti-sickling hemoglobin (HbA T87Q ) 15 months after treatment – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 1, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to
02/28/17
Summary Togglebluebird bio to Present at Two Investor Conferences in March CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
02/22/17
Summary Togglebluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress – Presented interim phase 1 dose escalation data for anti-BCMA CAR T product candidate in patients with relapsed/refractory multiple myeloma at EORTC-NCI-AACR Meeting – – Presented data from clinical studies of LentiGlobin TM drug product in patients with transfusion-dependent β-thalassemia (TDT)
02/03/17
Summary Togglebluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease - LentiGlobin TM drug product had a vector copy number (DP VCN) of 3.3 copies/diploid genome, with 83% of cells lentiviral vector sequence positive (LVV+) – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 3, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing
01/04/17
Summary Togglebluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2017-- bluebird bio, Inc. ( Nasdaq: BLUE ), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced today that Nick Leschly , chief

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.